[1]孙跃军,白洪林,王 栋,等.术前T2磁共振影像组学在预测介入治疗大肝癌近期疗效的研究 [J].介入放射学杂志,2019,28(11):1036-1041.
 SUN Yuejun,BAI Honglin,WANG Dong,et al.Preoperative T2 MRI radiomics signature in predicting the short- term efficacy of interventional therapy for large HCC: a clinical study[J].journal interventional radiology,2019,28(11):1036-1041.
点击复制

术前T2磁共振影像组学在预测介入治疗大肝癌近期疗效的研究
()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
28
期数:
2019年11期
页码:
1036-1041
栏目:
肿瘤介入
出版日期:
2019-11-25

文章信息/Info

Title:
Preoperative T2 MRI radiomics signature in predicting the short- term efficacy of interventional therapy for large HCC: a clinical study
作者:
孙跃军 白洪林 王 栋 冉 昭 徐李刚 钱 晟 杨国威 张 巍 王建华 高 欣 刘 嵘
Author(s):
SUN Yuejun BAI Honglin WANG Dong RAN Zhao XU Ligang QIAN Sheng YANG Guowei ZHANG Wei WANG Jianhua GAO Xin LIU Rong.
Department of Interventional Radiology, Affiliated Zhongshan Hospital, Fudan University, Shanghai 200032, China
关键词:
【关键词】 大肝癌 介入治疗 疗效预测 T2磁共振影像组学
文献标志码:
A
摘要:
【摘要】 目的 探讨基于介入术前MR的影像组学对肝癌6个月内介入治疗局部反应的预测价值。方法 回顾性分析70例接受介入治疗的大肝癌患者,术前1周内行MRI检查,术后1~ 2个月、半年随访多功能MRI,按照mRECIST标准对介入术后6个月肿瘤局部控制率进行评估,利用MITK软件在T2图像上进行勾画肿瘤区域,提取影像组学特征,利用Pearson相关系数剔除冗余特征,利用mRMR特征排序方法筛选得到组学标签。采用留一法划分样本,与LASSO分类器共同构建大肝癌介入治疗后6个月进展预测模型。计算模型的受试者工作特征曲线(ROC)的曲线下面积(AUC),评估模型的预测能力。结果 70例患者6个月后随访52例病灶未进展(N- PD),18例进展(PD),两组术前T2- MRI的Wavelet- HHH firstorder Mean等3个的影像组学参数有统计学差异(P<0.05),以这些差异性影像组学特征所建的模型具有一定的预测能力(AUC=0.657,ACC=0.714,SEN=0.588,SPE=0.755)。结论 基于MRI组学特征能对接受介入治疗的大肝癌进行近期进展风险预测,可在TACE术前筛选进展危险性高的患者,为其提早采取联合治疗提供个体化建议。

参考文献/References:

[1] Liu L, Chen H, Wang M, et al. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis[J]. PLoS One, 2014, 9: e91124.
[2] Wang Y, Ma L, Sheng S, et al. Combination therapy of TACE and CT- guided partial hepatic segment ablation for liver cancer[J]. Minim Invasive Ther Allied Technol, 2018, 27: 355- 364.
[3] Liu C, Liang P, Liu F, et al. MWA combined with TACE as a combined therapy forunresectable large- sized hepatocellular carcinoma[J]. Int J Hyperthermia, 2011, 27: 654- 662.
[4] Yang P, Liang M, Zhang Y, et al. Clinical application of a combination therapy of lentinan, multi- electrode RFA and TACE in HCC[J]. Adv Ther, 2008, 25: 787-794.
[5] Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study[J]. Cancer, 2015, 92: 1516-1524.
[6] Tang C, Shen J, Feng WM, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma: a retrospective study[J]. Medicine(Baltimore), 2016, 95: e3754.
[7] Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and prognosis of non- B, non- C hepatocellular carcinoma: a large retrospective multicenter cohort study[J]. J Gastroenterol, 2015, 50: 350-360.
[8] Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data[J]. Radiology, 2016, 278: 563-577.
[9] Wu M, Tan H, Gao F, et al. Predicting the grade of hepato- cellular carcinoma based on non- contrast- enhanced MRI radiomics signature[J]. Eur Radiol, 2018,[Epub ahead of print].
[10] Peng J, Zhang J, Zhang Q, et al. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus- related hepatocellular carcinoma[J]. Diagn Interv Radiol, 2018, 24: 121-127.
[11] Bakr S, Echegaray S, Shah R, et al. Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study[J]. J Med Imaging(Bellingham), 2017, 4: 041303.
[12] Hui TCH, Chuah TK, Low HM, et al. Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative MRI: a radiomics study[J]. Clin Radiol, 2018, 73: 1056.e11-1056.e16.
[13] Zhou Y, He L, Huang Y, et al. CT- based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma[J]. Abdom Radiol(NY), 2017, 42: 1695-1704.
[14] Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China(2017 edition)[J]. Liver Cancer, 2018, 7: 235-260.
[15] van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype[J]. Cancer Res, 2017, 77: e104- e107.
[16] Meng X, Xia W, Xie P, et al. Preoperative radiomic signature based on multiparametric magnetic resonance imaging for noninvasive evaluation of biological characteristics in rectal cancer[J]. Eur Radiol, 2019, 29: 3200- 3209.
[17] Huang YQ, Liang CH, He L, et al. Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer[J]. J Clin Oncol, 2016, 34: 2157-2164.
[18] Coroller TP, Grossmann P, Hou Y, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma[J]. Radiother Oncol, 2015, 114: 345-350.
[19] Liang C, Huang Y, He L, et al. The development and validation of a CT- based radiomics signature for the preoperative discrimination of stageⅠ-Ⅱand stageⅢ- Ⅳ colorectal cancer[J]. Oncotarget, 2016, 7: 31401- 31412.
[20] Markatou M, Tian H, Biswas S, et al. Analysis of variance of cross- validation estimators of the generalization error[J]. J Mach Learn Res, 2005, 6: 1127-1168.
[21] Njei B, Rotman Y, Ditah I, et al. Emerging trends in hepatocel-lular carcinoma incidence and mortality[J]. Hepatology, 2015, 61: 191-199.
[22] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66: 115-132.
[23] Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepato-cellular carcinoma[J]. Hepatology, 2002, 35: 1164-1171.
[24] 中国医师协会介入医师分会, 滕皋军, 安天志, 等. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 介入放射学杂志, 2018, 27: 1117-1126.
[25] Tandon P, Garcia- Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies[J]. Liver Interna-tional, 2009, 29: 502- 510.
[26] Wakai T, Shirai Y, Nomura T, et al. Computed tomographic features of hepatocellular carcinoma predict long- term survival after hepatic resection[J]. Eur J Surg Oncol, 2002, 28: 235-242.
[27] Goh BK, Chow PK, Teo JY, et al. Number of nodules,Child-Pugh status,margin positivity,and microvascular invasion,but not tumor size,are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma[J]. J Gastrointest Surg, 2014, 18: 1477-1485.
[28] 梁茂全, 苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J]. 介入放射学杂志, 2012, 21: 333-338.
[29] Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis[J]. Eur J Cancer, 2012, 48: 441- 446.
[30] Fu SR, Chen ST, Liang CH, et al. Texture analysis of intermediate- advanced hepatocellular carcinoma: prognosis and patients’ selection of transcatheter arterial chemoembolization and sorafenib[J]. Oncotarget, 2017, 8: 37855-37865.
[31] 徐 民, 程 雪, 赵中伟, 等. 超声, CT, MRI及DSA在肝癌介入综合治疗术后肿瘤活性评估中的对比价值研究[J]. 介入放射学杂志, 2018, 27: 363-366.
[32] 朱 正, 赵心明, 周纯武, 等. 体素内不相干运动扩散加权成像在肝癌介入治疗预后中的价值[J]. 肿瘤影像学, 2018, 27:24-29.
[33] Wang Q, Xia D, Bai W, et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study[J]. J Hepatol, 2019, 70: 893-903.

相似文献/References:

[1]王昌明,李 选,宋世兵,等.肝门部胆道引流管折叠技术在肝移植后胆道非吻合口狭窄治疗中的应用[J].介入放射学杂志,2012,(02):136.
 WANG Chang-ming,LI Xuan,SONG Shi-bing,et al.The application of biliary catheter folding technique in the treatment of hilar nonanastomotic biliary strictures after orthotopic liver transplantation[J].journal interventional radiology,2012,(11):136.
[2]赵玉峰,孙玉琴,韩晓静,等. 输卵管介入再通术后受孕时机的研究[J].介入放射学杂志,2012,(02):158.
 ZHAO Yu-feng,SUN Yu-qin,HAN Xiao-jing,et al.The optimal time for conception after fallopian tube recanalization therapy[J].journal interventional radiology,2012,(11):158.
[3]张海潇,顾俊鹏,迪里木拉提·巴吾冬,等.下肢缺血性疾病介入治疗的临床疗效分析[J].介入放射学杂志,2012,(02):111.
 ZHANG Hai-xiao,GU Jun-peng,BAWUDUN·Dilmurat,et al.Interventional therapy of lower limb ischemic diseases: a clinical therapeutic analysis[J].journal interventional radiology,2012,(11):111.
[4]何乾文,何远忠,罗来华,等.自制简易碘油推送器[J].介入放射学杂志,2000,(03):134.
[5]黄求理,宋侃侃,吴安乐,等.急性肢体动脉闭塞的血管内介入治疗[J].介入放射学杂志,2000,(03):155.
[6]陈伟敏,付晶,张树华,等.大剂量醛氢叶酸与5-氟尿嘧啶介入治疗晚期胃肠道癌[J].介入放射学杂志,2000,(03):181.
[7]郭添胜,姜在波,黄明声,等.原发性肝癌合并糖尿病介入治疗的围手术期处理[J].介入放射学杂志,2000,(03):182.
[8]张根山,周胜利,张旭.原发性肝癌合并脾功能亢进的介入治疗[J].介入放射学杂志,2000,(03):183.
[9]高爱荣,孙丰敏.血管内栓塞治疗脑动静脉畸形的护理[J].介入放射学杂志,2000,(03):138.
[10]王兴华,朱汉洲,李立.腹部手术后消化道出血的介入诊断与治疗[J].介入放射学杂志,2000,(04):240.
[11]李 臻,李一帆,余 鹏,等.经动脉载药微球化疗栓塞治疗大肝癌疗效的影响因素[J].介入放射学杂志,2023,32(08):781.
 LI Zhen,LI Yifan,YU Peng,et al.Factors influencing the effect of drug-eluting beads transarterial chemoembolization for large liver cancer[J].journal interventional radiology,2023,32(11):781.

备注/Memo

备注/Memo:
(收稿日期:2019-05-01)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2019-11-18